{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:28:25Z","timestamp":1794857305859,"version":"4.9.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1097\/hjh.0b013e3283455ca5","type":"journal-article","created":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T05:37:33Z","timestamp":1301463453000},"page":"980-990","source":"Crossref","is-referenced-by-count":243,"title":["A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism"],"prefix":"10.1097","volume":"29","author":[{"given":"Hari K","family":"Parthasarathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon H","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Miguel","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon T","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-24-20210208","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1210\/jc.2003-031337","article-title":"Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents","volume":"89","author":"Mulatero","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R2-24-20210208","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","article-title":"High incidence of primary aldosteronism in 199 patients referred with hypertension","volume":"21","author":"Gordon","year":"1994","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R3-24-20210208","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R4-24-20210208","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1210\/jc.2009-1399","article-title":"Update in primary aldosteronism","volume":"94","author":"Stowasser","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-24-20210208","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"R6-24-20210208","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cardiores.2003.11.037","article-title":"Review of aldosterone and angiotensin II induced target organ damage and prevention","volume":"61","author":"Struthers","year":"2004","journal-title":"Cardiovasc Res"},{"key":"R7-24-20210208","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA"},{"key":"R8-24-20210208","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/er.2007-0030","article-title":"A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function","volume":"29","author":"Connell","year":"2008","journal-title":"Endocr Rev"},{"key":"R9-24-20210208","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Intern Med"},{"key":"R10-24-20210208","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","article-title":"A review of the medical treatment of primary aldosteronism","volume":"19","author":"Lim","year":"2001","journal-title":"J Hypertens"},{"key":"R11-24-20210208","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11906-007-0009-3","article-title":"Mineralocorticoid receptor antagonists","volume":"9","author":"Parthasarathy","year":"2007","journal-title":"Curr Hypertens Rep"},{"key":"R12-24-20210208","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2003.10.008","article-title":"The 45-year story of the development of an antialdosterone more specific than spironolactone","volume":"217","author":"M\u00e9nard","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"R13-24-20210208","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"R14-24-20210208","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"R15-24-20210208","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","article-title":"Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension","volume":"92","author":"White","year":"2003","journal-title":"Am J Cardiol"},{"key":"R16-24-20210208","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"R17-24-20210208","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"R19-24-20210208","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14656566.9.4.509","article-title":"Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism","volume":"9","author":"Karagiannis","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R20-24-20210208","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1373\/clinchem.2008.118000","article-title":"Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement","volume":"55","author":"Campbell","year":"2009","journal-title":"Clin Chem"},{"key":"R21-24-20210208","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1097\/HJH.0b013e32833d2192","article-title":"The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma","volume":"28","author":"Rossi","year":"2010","journal-title":"J Hypertens"},{"key":"R22-24-20210208","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","article-title":"Committee on prevention, detection, evaluation, and treatment of high blood pressure.","volume":"157","year":"1997","journal-title":"Arch Intern Med"},{"key":"R23-24-20210208","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/archinte.159.7.693","article-title":"Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life","volume":"159","author":"Anderson","year":"1999","journal-title":"Arch Intern Med"},{"key":"R24-24-20210208","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R25-24-20210208","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"Sica","year":"2005","journal-title":"Heart Fail Rev"},{"key":"R26-24-20210208","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"key":"R27-24-20210208","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jama.1966.03110240051022","article-title":"Treatment of hypertension with spironolactone. Double-blind study","volume":"198","author":"Wolf","year":"1966","journal-title":"JAMA"},{"key":"R28-24-20210208","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"R29-24-20210208","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","article-title":"Efficacy of spironolactone therapy in patients with true resistant hypertension","volume":"55","author":"de Souza","year":"2010","journal-title":"Hypertension"},{"key":"R30-24-20210208","first-page":"462","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"1998","journal-title":"JASH"},{"key":"R32-24-20210208","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R33-24-20210208","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R34-24-20210208","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","article-title":"Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension","volume":"25","author":"Burgess","year":"2003","journal-title":"Clin Ther"},{"key":"R35-24-20210208","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/CIRCULATIONAHA.108.820472","article-title":"Patient health status and costs in heart failure: insights from the Eplerenone Postacute Myocardial Infarction Heart Failure Efficacy And Survival Study (EPHESUS)","volume":"119","author":"Chan","year":"2009","journal-title":"Circulation"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004872-201105000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T14:01:02Z","timestamp":1741096862000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-201105000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e3283455ca5","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}